Micro-Invasive Glaucoma Surgery (MIGS)
The treatment for glaucoma has come a long way. Today’s advanced technologies and procedures make it possible to diagnose and successfully manage this progressive disease. And while the overall goal of treatment has always remained the same — reducing intraocular pressure (IOP) and glaucomatous progression — Micro-Invasive Glaucoma Surgery (MIGS) is quickly becoming a widely accepted approach for treating mild-to-moderate glaucoma. 1
Glaucoma Therapy Advances
Glaucoma is primarily managed with prescription eye drops. If a patient’s glaucoma progresses or the patient stops responding to the eye drops, a surgical solution is offered. These surgical solutions are often highly invasive, require long recovery times, and could result in long-term complications.
As technology has progressed, less invasive techniques have emerged that have improved the safety profile for glaucoma surgery. This has opened more surgical options for patients interested in effective glaucoma management which does not rely solely on the continuous use of prescription medication.
A Revolution in Glaucoma Therapy
With the development of trabecular micro-bypass technologies, such as iStent inject®, Micro-Invasive Glaucoma Surgery (MIGS) has become the preferred approach to glaucoma management for many eye care professionals and their patients with mild-to-moderate primary open-angle glaucoma. iStent inject® has proven to be effective in decreasing IOP, with an excellent safety profile, few complications, and fast recovery time.2
iStent inject® may also reduce patients’ need for medications as determined by an eye care professional. In one study, the majority of patients who received iStent inject® were either medication-free or on only 1 medication at 18 months.3 Other benefits associated with this innovative treatment include:
• Minimally traumatic to delicate eye tissue
• Effectively lowers IOP
• Excellent safety profile
• Rapid recovery
1. Marketscope 2015
2.Voskanyan L, García-Feijoó J, Belda J, Fea A, Jünemann A, Baudouin C. Prospective, Unmasked Evaluation of the iStent inject System for Open-Angle Glaucoma: Synergy Trial. Adv Ther 2014;31:189-201.
3.Hengerer FH, Müller M, Conrad-Hengerer I, Kohnen T. Personal experience and outcomes through eighteen months following implantation of second generation trabecular micro-bypass stents in patients with open-angle glaucoma. Presented at the 2016 European Society of Cataract and Refractive Surgery Annual Meeting; September 13-17, 2016; Cophenhagen, Denmark.
Speak with an iStent inject® Physician Today
Help is right around the corner. Leading eye professionals offer iStent inject® for the treatment and control of eye pressure associated with mild-to-moderate primary open-angle glaucoma, and are available to answer your questions. Find out if you are a candidate for inject® by talking with a Physician in your area today.Find an iStent inject® Physician